Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Global X Uranium ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Global X Uranium ETF trades at $34.76 (market cap $5.50B). The key difference: Global X Uranium ETF is far larger — about 5.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Global X Uranium ETF for 64 Days on average.
| MRVI | URA | |
|---|---|---|
Market Cap | $972.90M | $5.50B |
Volume | 4,325,710 | 3,413,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $9.00 | $61.81 |
52-Week Low | $2.83 | $35.54 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
URA (Global X Uranium ETF) trades at $37.38, down 0.9% with a bearish technical signal from moving averages. The ETF provides diversified exposure to uranium miners and nuclear energy companies amid growing global nuclear adoption. Recent news highlights nuclear energy's role in meeting AI power demand and government support for reactor development. Key holdings include Cameco (over 20%) and Sprott Physical Uranium Trust (nearly 6%).
Outlook remains mixed with strong long-term nuclear demand drivers offset by recent sector volatility. Investment opportunity lies in nuclear's capacity factor advantages and policy support, while risks include uranium price fluctuations and concentrated holdings. The ETF's 18.9% correction presents potential entry point for thematic investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
